Device Trial Radar · NCT03499821
Clinical Performance of a Phakic Intraocular Lens (IOL)
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Mar 20, 2018
Primary completion
Jul 9, 2019
Study completion Jul 9, 2019
Sponsor
- Lead sponsor
- Staar Surgical CompanyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 17, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.
Conditions
- Presbyopia
Interventions
EDOF ICLDevice
The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Eyes With Monocular Uncorrected Near Visual Acuity of 20/40 or Better at 40 cm 6 Months After ImplantationTime frame: 6 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Mediopolis
Antwerp, Belgium
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.